March 26, 2019 / 11:50 PM / 3 months ago

BRIEF-Novartis Receives FDA Approval For Mayzent

March 26 (Reuters) - Novartis AG:

* NOVARTIS RECEIVES FDA APPROVAL FOR MAYZENT® (SIPONIMOD), THE FIRST ORAL DRUG TO TREAT SECONDARY PROGRESSIVE MS WITH ACTIVE DISEASE

* NOVARTIS - MAYZENT IS FIRST, ONLY TREATMENT SPECIFICALLY APPROVED FOR PATIENTS WITH ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN OVER 15 YEARS

* FDA APPROVAL OF MAYZENT DRUG IS BASED ON PHASE III EXPAND TRIAL

* MAYZENT IS EXPECTED TO BE AVAILABLE IN U.S. IN APPROXIMATELY ONE WEEK

* NOVARTIS - MAYZENT IS APPROVED ACROSS THE MS SPECTRUM FOR CLINICALLY ISOLATED SYNDROME, RRMS, ACTIVE SPMS

* NOVARTIS - REGULATORY ACTION FOR MAYZENT IN EU ANTICIPATED IN LATE 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below